These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23242809)

  • 21. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
    Gupta M; Hendrickson AE; Yun SS; Han JJ; Schneider PA; Koh BD; Stenson MJ; Wellik LE; Shing JC; Peterson KL; Flatten KS; Hess AD; Smith BD; Karp JE; Barr S; Witzig TE; Kaufmann SH
    Blood; 2012 Jan; 119(2):476-87. PubMed ID: 22080480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice.
    Hussain S; Bedekovics T; Liu Q; Hu W; Jeon H; Johnson SH; Vasmatzis G; May DG; Roux KJ; Galardy PJ
    Blood; 2018 Dec; 132(24):2564-2574. PubMed ID: 30257881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
    Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
    Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.
    Fujishita T; Aoki K; Lane HA; Aoki M; Taketo MM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13544-9. PubMed ID: 18768809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
    Wang J; Boxer LM
    J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
    Tamburini J; Green AS; Bardet V; Chapuis N; Park S; Willems L; Uzunov M; Ifrah N; Dreyfus F; Lacombe C; Mayeux P; Bouscary D
    Blood; 2009 Aug; 114(8):1618-27. PubMed ID: 19458359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant mice lacking alternatively spliced p53 isoforms unveil
    Fajac A; Simeonova I; Leemput J; Gabriel M; Morin A; Lejour V; Hamon A; Rakotopare J; Vaysse-Zinkhöfer W; Eldawra E; Pinskaya M; Morillon A; Bourdon JC; Bardot B; Toledo F
    Elife; 2024 Sep; 13():. PubMed ID: 39298333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
    Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
    Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.
    Sheikh BN; Lee SC; El-Saafin F; Vanyai HK; Hu Y; Pang SH; Grabow S; Strasser A; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T
    Blood; 2015 Mar; 125(12):1910-21. PubMed ID: 25605372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
    Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
    PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.
    Astle MV; Hannan KM; Ng PY; Lee RS; George AJ; Hsu AK; Haupt Y; Hannan RD; Pearson RB
    Oncogene; 2012 Apr; 31(15):1949-62. PubMed ID: 21909130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
    Carracedo A; Ma L; Teruya-Feldstein J; Rojo F; Salmena L; Alimonti A; Egia A; Sasaki AT; Thomas G; Kozma SC; Papa A; Nardella C; Cantley LC; Baselga J; Pandolfi PP
    J Clin Invest; 2008 Sep; 118(9):3065-74. PubMed ID: 18725988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
    Nölting S; Garcia E; Alusi G; Giubellino A; Pacak K; Korbonits M; Grossman AB
    J Mol Endocrinol; 2012 Oct; 49(2):79-96. PubMed ID: 22715163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cdk2 suppresses cellular senescence induced by the c-myc oncogene.
    Campaner S; Doni M; Hydbring P; Verrecchia A; Bianchi L; Sardella D; Schleker T; Perna D; Tronnersjö S; Murga M; Fernandez-Capetillo O; Barbacid M; Larsson LG; Amati B
    Nat Cell Biol; 2010 Jan; 12(1):54-9; sup pp 1-14. PubMed ID: 20010815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTORC1 promotes survival through translational control of Mcl-1.
    Mills JR; Hippo Y; Robert F; Chen SM; Malina A; Lin CJ; Trojahn U; Wendel HG; Charest A; Bronson RT; Kogan SC; Nadon R; Housman DE; Lowe SW; Pelletier J
    Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10853-8. PubMed ID: 18664580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.
    Happo L; Phipson B; Smyth GK; Strasser A; Scott CL
    Cell Death Dis; 2012 May; 3(5):e306. PubMed ID: 22573037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus tablets for patients with subependymal giant cell astrocytoma.
    Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
    Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.